$12.71
▼ -0.6% Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics to Present at September Investor Conferences
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?
Overview
52-week range
$4.35
$14
87% of range
Avg surprise (last 3)
+79.2%
Avg reaction (last 2)
+3.7%
50% positive
Latest IV / EM
238%
EM ±38.6% · $13 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.52 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-0.14 | $-0.22 | +36.4% | -207.7% | -0.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.09 | $-0.17 | +47.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $0.13 | $-0.24 | +154.2% | — | +7.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.33 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.74 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.28 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.29 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.33 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.30 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | $-16M | — | $-13M | $-11M | $-8M | — | $-9M |
| Net income | $-39M | $-9M | — | $-11M | $-5M | $7M | — | $-11M |
| EPS (diluted) | $-0.52 | $-0.14 | — | $-0.21 | $-0.09 | $0.13 | — | $-0.33 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $202M | $195M | $120M | $87M | $101M | $92M | $103M | $17M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $204M | $198M | $121M | $90M | $104M | $93M | $104M | $18M |
| Total assets | $208M | $202M | $125M | $94M | $106M | $96M | $107M | $22M |
| Long-term debt | — | — | — | — | — | — | — | $4M |
| Total liabilities | $82M | $64M | $73M | $13M | $16M | $21M | $41M | $37M |
| Total equity | $126M | $138M | $52M | $80M | $90M | $75M | $66M | $-15M |